Hormone abuse, in sports: the antidoping perspective

被引:44
作者
Barroso, Osquel [1 ]
Mazzoni, Irene [1 ]
Rabin, Olivier [1 ]
机构
[1] WADA, Dept Sci, Montreal, PQ H4Z 1B7, Canada
关键词
World Anti-Doping Agency; doping; hormone; sport;
D O I
10.1111/j.1745-7262.2008.00402.x
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of doping substances. A list of doping substances and methods banned in sports is published yearly by the World Anti-Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following criteria: enhances sports performance; represents a risk to the athlete's health; or violates the spirit of sports. This list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends, enumerates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal and peptide hormones and their modulators, stimulants, glucocorticosteroids, beta 2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of molecular biology techniques has made recombinant peptide hormones readily available. These substances are gradually changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone (hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement. Furthermore, as there is a paucity of techniques suitable for their detection, peptide hormones are all the more attractive to dishonest athletes. This article will overview the use of hormones as doping substances in sports, focusing mainly on peptide hormones as they represent a pressing challenge to the current fight against doping. Hormones and hormones modulators being developed by the pharmaceutical industry, which could emerge as new doping substances, are also discussed.
引用
收藏
页码:391 / 402
页数:12
相关论文
共 128 条
[11]   Approach to the determination of insulin-like-growth-factor-I (IGF-I) concentration in plasma by high-performance liquid chromatography-ion trap mass spectrometry: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization [J].
Bobin, S ;
Popot, MA ;
Bonnaire, Y ;
Tabet, JC .
ANALYST, 2001, 126 (11) :1996-2001
[12]   Functional improvement of dystrophic muscle by myostatin blockade [J].
Bogdanovich, S ;
Krag, TOB ;
Barton, ER ;
Morris, LD ;
Whittemore, LA ;
Ahima, RS ;
Khurana, TS .
NATURE, 2002, 420 (6914) :418-421
[13]   Myostatin propeptide-mediated amelioration of dystrophic pathophysiology [J].
Bogdanovich, S ;
Perkins, KJ ;
Krag, TOB ;
Whittemore, SA ;
Khurana, TS .
FASEB JOURNAL, 2005, 19 (06) :543-549
[14]  
Bowers LD, 1997, CLIN CHEM, V43, P1299
[15]  
Bowsher RR, 1999, CLIN CHEM, V45, P104
[16]   Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men [J].
Brill, KT ;
Weltman, AL ;
Gentili, A ;
Patrie, JT ;
Fryburg, DA ;
Hanks, JB ;
Urban, RJ ;
Veldhuis, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12) :5649-5657
[17]   Aromatase and its inhibitors [J].
Brodie, A ;
Lu, Q ;
Long, B .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 69 (1-6) :205-210
[18]   MORTALITY, NEOPLASIA, AND CREUTZFELDT-JAKOB DISEASE IN PATIENTS TREATED WITH HUMAN PITUITARY GROWTH-HORMONE IN THE UNITED-KINGDOM [J].
BUCHANAN, CR ;
PREECE, MA ;
MILNER, RDG .
BRITISH MEDICAL JOURNAL, 1991, 302 (6780) :824-828
[19]  
Butler SA, 2001, CLIN CHEM, V47, P2131
[20]  
Catlin DH, 2002, CLIN CHEM, V48, P2057